U
ULTRAGENYX
NASDAQ: RARE (Ultragenyx Pharmaceutical Inc.)
Last update: 2 hours ago21.34
-0.37 (-1.70%)
| Previous Close | 21.71 |
| Open | 21.94 |
| Volume | 2,542,744 |
| Avg. Volume (3M) | 2,815,493 |
| Market Cap | 2,062,079,744 |
| Price / Sales | 3.35 |
| Price / Book | 247.70 |
| 52 Weeks Range | |
| Earnings Date | 5 May 2026 |
| Profit Margin | -93.04% |
| Operating Margin (TTM) | -102.62% |
| Diluted EPS (TTM) | -5.83 |
| Quarterly Revenue Growth (YOY) | 28.00% |
| Total Debt/Equity (MRQ) | 588.24% |
| Current Ratio (MRQ) | 2.40 |
| Operating Cash Flow (TTM) | -389.94 M |
| Levered Free Cash Flow (TTM) | -172.94 M |
| Return on Assets (TTM) | -24.51% |
| Return on Equity (TTM) | -377.06% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | Ultragenyx Pharmaceutical Inc. | Bearish | Bearish |
AIStockmoo Score
1.7
| Analyst Consensus | 4.0 |
| Insider Activity | 1.0 |
| Price Volatility | 0.5 |
| Technical Moving Averages | 3.5 |
| Technical Oscillators | -0.5 |
| Average | 1.70 |
|
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 3.20% |
| % Held by Institutions | 99.43% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Sands Capital Management, Llc | 31 Dec 2025 | 3,485,724 |
| Rtw Investments, Lp | 31 Dec 2025 | 3,000,139 |
| Baker Bros. Advisors Lp | 31 Dec 2025 | 2,772,692 |
| Frontier Capital Management Co Llc | 31 Dec 2025 | 1,965,084 |
| Bnp Paribas Asset Management Holding S.A. | 31 Dec 2025 | 1,899,661 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 79.00 (Canaccord Genuity, 270.20%) | Buy |
| Median | 51.00 (138.99%) | |
| Low | 25.00 (Wedbush, 17.15%) | Hold |
| Average | 52.30 (145.08%) | |
| Total | 9 Buy, 1 Hold | |
| Avg. Price @ Call | 21.91 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Canaccord Genuity | 18 Feb 2026 | 79.00 (270.20%) | Buy | 20.45 |
| Evercore ISI Group | 18 Feb 2026 | 34.00 (59.33%) | Buy | 20.45 |
| 17 Feb 2026 | 37.00 (73.38%) | Buy | 20.18 | |
| HC Wainwright & Co. | 17 Feb 2026 | 50.00 (134.30%) | Buy | 20.18 |
| 03 Feb 2026 | 60.00 (181.16%) | Buy | 24.80 | |
| Wedbush | 17 Feb 2026 | 25.00 (17.15%) | Hold | 20.18 |
| Guggenheim | 05 Jan 2026 | 52.00 (143.67%) | Buy | 23.11 |
| B of A Securities | 02 Jan 2026 | 58.00 (171.79%) | Buy | 23.60 |
| Baird | 30 Dec 2025 | 47.00 (120.24%) | Buy | 22.78 |
| Jefferies | 30 Dec 2025 | 63.00 (195.22%) | Buy | 22.78 |
| Leerink Partners | 30 Dec 2025 | 70.00 (228.02%) | Buy | 22.78 |
| Wells Fargo | 30 Dec 2025 | 45.00 (110.87%) | Buy | 22.78 |
| Show more | ||||
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| CROMBEZ ERIC | 23.39 | 23.02 | 4,614 | 110,522 |
| HARRIS ERIK | 23.39 | 23.02 | 1,104 | 29,722 |
| HORN HOWARD | 23.39 | 22.55 | -3,901 | -85,975 |
| HUANG DENNIS KARL | 23.39 | 23.02 | 10,138 | 237,497 |
| HUIZENGA THEODORE ALAN | - | 23.02 | -1,780 | -40,976 |
| KAKKIS EMIL D | 23.39 | 23.02 | 16,773 | 412,450 |
| PARSCHAUER KARAH HERDMAN | 23.39 | 22.37 | -6,524 | -134,778 |
| PINION JOHN RICHARD | 23.39 | 23.02 | 1,108 | 29,627 |
| Aggregate Net Quantity | 21,532 | |||
| Aggregate Net Value ($) | 558,089 | |||
| Aggregate Avg. Buy ($) | 23.39 | |||
| Aggregate Avg. Sell ($) | 22.78 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| PARSCHAUER KARAH HERDMAN | Officer | 10 Mar 2026 | Sell (-) | 3,508 | 22.84 | 80,123 |
| PARSCHAUER KARAH HERDMAN | Officer | 06 Mar 2026 | Sell (-) | 6,018 | 21.25 | 127,883 |
| HORN HOWARD | Officer | 03 Mar 2026 | Sell (-) | 1,635 | 22.07 | 36,084 |
| HUANG DENNIS KARL | Officer | 02 Mar 2026 | Disposed (-) | 999 | 23.02 | 22,997 |
| CROMBEZ ERIC | Officer | 02 Mar 2026 | Sell (-) | 7,029 | 23.02 | 161,808 |
| HORN HOWARD | Officer | 02 Mar 2026 | Sell (-) | 8,409 | 23.02 | 193,575 |
| HUIZENGA THEODORE ALAN | Officer | 02 Mar 2026 | Disposed (-) | 148 | 23.02 | 3,407 |
| HUIZENGA THEODORE ALAN | Officer | 02 Mar 2026 | Sell (-) | 1,632 | 23.02 | 37,569 |
| PARSCHAUER KARAH HERDMAN | Officer | 02 Mar 2026 | Sell (-) | 8,135 | 23.02 | 187,268 |
| KAKKIS EMIL D | Officer | 02 Mar 2026 | Sell (-) | 54,404 | 23.02 | 1,252,380 |
| HARRIS ERIK | Officer | 02 Mar 2026 | Sell (-) | 10,539 | 23.02 | 242,608 |
| PINION JOHN RICHARD | Officer | 02 Mar 2026 | Sell (-) | 10,029 | 23.02 | 230,868 |
| HUANG DENNIS KARL | Officer | 01 Mar 2026 | Acquired (+) | 11,137 | 23.39 | 260,494 |
| CROMBEZ ERIC | Officer | 01 Mar 2026 | Acquired (+) | 11,643 | 23.39 | 272,330 |
| HORN HOWARD | Officer | 01 Mar 2026 | Acquired (+) | 6,143 | 23.39 | 143,685 |
| PARSCHAUER KARAH HERDMAN | Officer | 01 Mar 2026 | Acquired (+) | 11,137 | 23.39 | 260,494 |
| KAKKIS EMIL D | Officer | 01 Mar 2026 | Acquired (+) | 71,177 | 23.39 | 1,664,830 |
| HARRIS ERIK | Officer | 01 Mar 2026 | Acquired (+) | 11,643 | 23.39 | 272,330 |
| PINION JOHN RICHARD | Officer | 01 Mar 2026 | Acquired (+) | 11,137 | 23.39 | 260,494 |
| Show more | ||||||
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |